(Reuters) -Advisers to the U.S. Food and Drug Administration will discuss whether to recommend COVID-19 vaccines for 2025-26 for targetting the LP.8.1 subvariant, documents filed on Tuesday showed.
The panel of advisers will make recommendations on the selection of the 2025-2026 formula for COVID-19 vaccines for use in the United States on Thursday.
(Reporting by Puyaan Singh and Christy Santhosh in Bengaluru; Editing by Anil D’Silva)
Comments